-
Mashup Score: 1
Oral and Poster Abstracts 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I Adults, Clinical Research, Diseases, Myeloid Malignancies, Study Population Paul G. Richardson, MD1,2, Ruben Niesvizky, MD3, Jay Yang, PhD4*, Neelu Yadav, PhD4*, Helen Hsu, MD4* and Christopher R. Flowers51Medical Oncology,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Oral and Poster Abstracts 602. Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic: Poster I Fundamental Science, Biological, Clinically Relevant, Diseases, Therapies Jennifer Totman*, Dorothy Brach*, Vinny Motwani*, Selene Howe*, Emily Deutschman*, John Lampe*, Thomas V. Riera*, Cuyue Tang*, Sean T. Eckley*, Josh Alford*,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in RRMM & DLBCL [Nov 5, 2021] Totman et al. @EpizymeRx Abstract 1142 #ASH21 https://t.co/AHngB2971k #SETD2 #mmsm #lymsm #caxtx
-
-
Mashup Score: 0
Oral and Poster Abstracts 602. Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic: Poster I Fundamental Science, Biological, Clinically Relevant, Diseases, Therapies Jennifer Totman*, Dorothy Brach*, Vinny Motwani*, Selene Howe*, Emily Deutschman*, John Lampe*, Thomas V. Riera*, Cuyue Tang*, Sean T. Eckley*, Josh Alford*,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in RRMM & DLBCL [Nov 5, 2021] Totman et al. @EpizymeRx Abstract 1142 #ASH21 https://t.co/AHngB2971k #SETD2 #mmsm #lymsm #caxtx
-
-
Mashup Score: 0Roles of SETD2 in Leukemia—Transcription, DNA-Damage, and Beyond - 2 year(s) ago
The non-redundant histone methyltransferase SETD2 (SET domain containing 2; KMT3A) is responsible for tri-methylation of lysine 36 on histone H3 (H3K36me3). Presence of the H3K36me3 histone mark across the genome has been correlated with transcriptional activation and elongation, but also with the regulation of DNA mismatch repair, homologous recombination and alternative splicing. The role of…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet-
Roles of SETD2 in Leukemia -- Transcription, DNA-Damage, and Beyond [Feb 27, 2019] @anna_skucha @JessicaEbner92 @florian_grebien @IJMS_MDPI https://t.co/tdyGrpsson #SETD2 #leusm #mmsm https://t.co/59yt1bD60Z
-
-
Mashup Score: 3
Oral and Poster Abstracts 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I Adults, Clinical Research, Diseases, Myeloid Malignancies, Study Population Paul G. Richardson, MD1,2, Ruben Niesvizky, MD3, Jay Yang, PhD4*, Neelu Yadav, PhD4*, Helen Hsu, MD4* and Christopher R. Flowers51Medical Oncology,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Phase 1/1b Open-Label, Multicenter, Two-Part Study of SETD2 Inhibitor EZM0414 in Pts w/ Relapsed/Refractory Multiple Myeloma or Diffuse Large B-Cell Lymphoma [Nov 5, 2021] Richardson et al. @ChrisRFlowersMD Abst 1679 #ASH21 https://t.co/H97RBtJJRR @EpizymeRx #SETD2 #mmsm #lymsm
-
-
Mashup Score: 1The Multiple Myeloma Daily - 3 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/050XdypBQz Thanks to @ASCOPost @mtmdphd #mmsm #setd2
-
-
Mashup Score: 1
Translocation t(4;14) is an independent prognostic factor for adverse outcome in multiple myeloma (MM). However, reports concerning the therapeutic effects of novel drugs on t(4;14) MM are few. We retrospectively investigated the clinical and prognostic significance of symptomatic MM cases with t(4;14) treated with novel therapies. Ninety-three patients (IgG, 56; IgA, 23; BjP, 14) newly diagnosed…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Clinical and Prognostic Significance of t(4;14) Translocation in Multiple Myeloma in the Era of Novel Agents [Sep 19, 2020] Sato et al. Int J Hematol https://t.co/jYf7XQ5keL #SETD2 #mmsm #PrecisionMedicine #caxtx Japan, n=93 NDMM. In n=17 (18%) t(4;14) MVA = worse OS HR: 7.58
-
-
Mashup Score: 1
Cell Research –
Source: Cell ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
SETD2 -- linking stem cell survival and transformation [Mar 23, 2018] @MrinalPatnaik & Omar Abdel-Wahab @cell_res https://t.co/XEurTGOI35 #SETD2 #PrecisionMedicine #caxtx https://t.co/XZWpEM0Yt4
-
-
Mashup Score: 4
Translocation t(4;14) is an independent prognostic factor for adverse outcome in multiple myeloma (MM). However, reports concerning the therapeutic effects of novel drugs on t(4;14) MM are few. We retrospectively investigated the clinical and prognostic significance of symptomatic MM cases with t(4;14) treated with novel therapies. Ninety-three patients (IgG, 56; IgA, 23; BjP, 14) newly diagnosed…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Clinical and Prognostic Significance of t(4;14) Translocation in Multiple Myeloma in the Era of Novel Agents [Sep 19, 2020] Sato et al. Int J Hematol https://t.co/jYf7XQ5keL #SETD2 #mmsm #PrecisionMedicine #caxtx Japan, n=93 NDMM. In n=17 (18%) t(4;14) MVA = worse OS HR: 7.58
-
-
Mashup Score: 0The Multiple Myeloma Daily - 3 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/73sXZzqXV8 Thanks to @IMFjimMYELOMA @mtmdphd #mmsm #setd2
-
Phase 1/1b Open-Label, Multicenter, Two-Part Study of SETD2 Inhibitor EZM0414 in Pts w/ Relapsed/Refractory Multiple Myeloma or Diffuse Large B-Cell Lymphoma [Nov 5, 2021] Richardson et al. @ChrisRFlowersMD Abst 1679 #ASH21 https://t.co/H97RBtJJRR @EpizymeRx #SETD2 #mmsm #lymsm